Shengwen Calvin Li, PhD

Neuro-Oncology and Stem Cell Research Laboratory, Center for Neuroscience Research, CHOC Children's Hospital, University of California Irvine School of Medicine, Orange, CA, USA

Dr. Li has 148+ publications including the peer-reviewed research articles, reviews, book chapters, and patent applications. His publications have been remarked in articles published in Nature, Science, Cell, and Annual Reviews of Cell and Developmental Biology, with total citations of 7,000+. His publication was on top 50 most-frequently-cited Journal of Biological Chemistry (JBC) Articles (#49) in 2004; on top 40 in 2005 and 2006, respectively. His recent research was highlighted on the cover of August 2011 issue of Proceedings of the National Academy of Sciences of USA. His publications identify Caveolin-Scaffolding Domain (CSD) and CSD-interacting motif (CIM), spring up research on caveolin-mediated signaling and related diseases – both terms are well adopted in literature and textbooks. His research helps lead to $2.9 billion agreement for targeting a previously unrecognized tumor-activated, albumin-specific biologic pathway with a nanoshell of the human blood protein albumin in 2011. This nano-shuttle system is believed to activate an albumin-specific (Gp60) receptor-mediated transcytosis path through the cell wall of proliferating tumor cells, using caveolin-1 activated caveolar transport. He led to complete sequencing of whole genome for Botulinum neurotoxin Type A-Hall (Allergan BOTOX®) Strain, from which BOTOX® branded therapeutic products are manufactured with annual sale of $1.3 billion. He publication “A biological global positioning system (GPS): considerations for tracking stem cell behaviors in the whole body” was on feature story: Commented by Jeffrey M. Perkel, Ph.D., in BioTechniques Focus: Translational Tools – Special News Feature entitled “What lies beneath: In vivo stem cell imaging,” BioTechniques. He published a concept “therapeutic window” as a tool for personalized treatment of cancer.

He has been a member of Association for Clinical and Translational Science (ACTS), Society for Translational and Clinical Sciences, International Society of Stem Cell Research (ISSCR), Society for Neuroscience (SfN), American Society for Cell Biology (ASCB), American Association for the Advancement of Science (AAAS), American Society for Neurochemistry (ASN), and American Society of Investigative Pathology (ASIP). 

He has served on the editorial board of American Journal of Pathology ((Official Journal of ASIP) since 2008, on the editorial board (section editor) of the Journal of Stem Cell & Therapy since 2011, on the editorial board of the World Journal of Stem Cells since 2012, the editorial board of the MOJ Cell Science & Reports since 2014, the editorial board of for the journal Current Stem Cell Research & Therapy (Bentham Science Publishers) since 2015. He has also served on an ad-hoc reviewer for many other journals and grant agencies. 

Research Interest

Pediatric brain tumor biology, stem cell differentiation mechanisms, stem cell-based therapy, engineered tissue graft, engineer-design matrix for cell and organ culture, Caveolin-mediated signal transduction, immunotherapy of cancer, real-time imaging for tumor progression and stem cell development, precision medicine.